PMC:547907 / 4546-5854 JSONTXT

{"project":"2_test","denotations":[{"id":"15667657-9881538-13782176","span":{"begin":573,"end":575},"obj":"9881538"}],"text":"Patients\nForty two subjects aged 18–65 years inclusive were recruited in our multi-centre study comprising five sites in South Africa and one in Canada. Recruitment took place between May 2002 and November 2003. Prior to commencement, all sites in the study received approval from their relevant Research Ethics committees/Institutional review boards and regulatory authorities. All subjects provided written informed consent prior to the commencement of any study-related procedures. Diagnosis was confirmed using the MINI Neuropsychiatric Interview (Version 5.00, 1998) [28] to ensure compatibility with the Diagnostic and Statistical Manual for Mental Disorders, Fourth Edition (DSM-IVTR)[29] criteria for OCD. Subjects with any co-existing Axis I disorder were excluded unless the co-morbid condition was deemed to be secondary to the OCD. Female subjects of childbearing potential were required to use adequate contraception and were not permitted to breastfeed while on the study. Subjects were excluded if they suffered from unstable medical conditions including renal or hepatic insufficiency, epilepsy or had suffered previous brain injury or undergone brain surgery. Taking medication that was deemed likely to interact with quetiapine or any other psychoactive substance was grounds for exclusion."}

{"project":"NEUROSES","denotations":[{"id":"T158","span":{"begin":587,"end":600},"obj":"PATO_0000021"},{"id":"T159","span":{"begin":682,"end":685},"obj":"CHEBI_38624"},{"id":"T160","span":{"begin":822,"end":831},"obj":"PATO_0002532"},{"id":"T161","span":{"begin":844,"end":850},"obj":"PATO_0000383"},{"id":"T162","span":{"begin":907,"end":915},"obj":"PATO_0001627"},{"id":"T163","span":{"begin":1235,"end":1245},"obj":"CHEBI_8707"},{"id":"T164","span":{"begin":1272,"end":1281},"obj":"PATO_0000142"}],"text":"Patients\nForty two subjects aged 18–65 years inclusive were recruited in our multi-centre study comprising five sites in South Africa and one in Canada. Recruitment took place between May 2002 and November 2003. Prior to commencement, all sites in the study received approval from their relevant Research Ethics committees/Institutional review boards and regulatory authorities. All subjects provided written informed consent prior to the commencement of any study-related procedures. Diagnosis was confirmed using the MINI Neuropsychiatric Interview (Version 5.00, 1998) [28] to ensure compatibility with the Diagnostic and Statistical Manual for Mental Disorders, Fourth Edition (DSM-IVTR)[29] criteria for OCD. Subjects with any co-existing Axis I disorder were excluded unless the co-morbid condition was deemed to be secondary to the OCD. Female subjects of childbearing potential were required to use adequate contraception and were not permitted to breastfeed while on the study. Subjects were excluded if they suffered from unstable medical conditions including renal or hepatic insufficiency, epilepsy or had suffered previous brain injury or undergone brain surgery. Taking medication that was deemed likely to interact with quetiapine or any other psychoactive substance was grounds for exclusion."}